JNM CE/SAM (November 2022): Oligometastatic Prostate Cancer: Current Status and Future Challenges
JNM, November 2022, Volume 63, Number 11
Release Date: November 1, 2022
Expiration Date: November 30, 2025
SNMMI Members: Free
Non-Members: $69.00
Continuing Education Credit Information
ABNM SAM Credit
The American Board of Nuclear Medicine has reviewed and approved this Journal SAM activity submitted by the SNMMI. This activity fulfills the requirements of the ABNM Maintenance of Certification program for self-assessment. 2.0 SAMs have been awarded for this activity.
AMA-PRA (Physician)
The Society for Nuclear Medicine and Medical Imaging, Inc. (SNMMI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. SNMMI designates this enduring material for a maximum of 2.0 AMA PRA Category 1 CreditsTM. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Authors
Hossein Jadvar1, Andre Luis Abreu2, Leslie K. Ballas3, and David I. Quinn4
1Department of Radiology, Kenneth J. Norris, Jr., Comprehensive Cancer Center, USC Keck School of Medicine, University of Southern California, Los Angeles, California; 2Institute of Urology, Kenneth J. Norris, Jr., Comprehensive Cancer Center, USC Keck School of Medicine, University of Southern California, Los Angeles, California; 3Department of Radiation Oncology, Kenneth J. Norris, Jr., Comprehensive Cancer Center, USC Keck School of Medicine, University of Southern California, Los Angeles, California; and 3Division of Cancer Medicine, Department of Medicine, Kenneth J. Norris, Jr., Comprehensive Cancer Center, USC Keck School of Medicine, University of Southern California, Los Angeles, California
Disclosure
This work was supported in part by grant P30‐CA014089 from the U.S. National Institutes of Health. Dr. Jadvar is on the advisory board of Radiomedix, Inc., and Pharmalogic, is on the speakers’ bureau for Lantheus, and is a consultant to Bayer and Blue Earth Diagnostics. Dr. Abreu is a consultant to Koelis. Dr. Quinn receives payment for advisory board and consulting services to, and is an investigator for, Astellas, Pfizer, Bayer Healthcare, Novartis, and Merck; receives stock options from Abbvie; and is employed by Abbvie. Dr. Ballas is employed by Cedars–Sinai Medical Center. In accordance with ACCME Revised Standards for Commercial Support and SNMMI Conflict-of-Interest Policy, the authors have indicated no other relevant relationships that could be perceived as a real or apparent conflict of interest. Disclosure of a relationship is not intended to suggest or to condone bias but is made to provide participants with information that might be of potential importance to their evaluation of the activity.
Target Audience
This article contains information of value to nuclear medicine professionals interested in the concept of oligometastatic prostate cancer and how nuclear medicine may be contributory, including physicians, technologists, scientists, and those in training.
Objectives
On successful completion of this activity, participants should be able to…
1. Describe the clinical state of oligometastatic disease along the natural history of prostate cancer.
2. Discuss the outcome results of the various clinical trials on metastasis-directed therapy of oligometastatic disease in prostate cancer.
3. Recognize the gaps in knowledge and needed additional areas of research relevant to oligometastatic prostate cancer.
Contact Information
For questions please contact Lisa Dickinson, Associate Director of Education at ldickinson@snmmi.org or 703-652-6783.
JNM, November 2022, Volume 63, Number 11
Release Date: November 1, 2022
Expiration Date: November 30, 2025
SNMMI Members: Free
Non-Members: $69.00
Continuing Education Credit Information
ABNM SAM Credit
The American Board of Nuclear Medicine has reviewed and approved this Journal SAM activity submitted by the SNMMI. This activity fulfills the requirements of the ABNM Maintenance of Certification program for self-assessment. 2.0 SAMs have been awarded for this activity.
AMA-PRA (Physician)
The Society for Nuclear Medicine and Medical Imaging, Inc. (SNMMI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. SNMMI designates this enduring material for a maximum of 2.0 AMA PRA Category 1 CreditsTM. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Authors
Hossein Jadvar1, Andre Luis Abreu2, Leslie K. Ballas3, and David I. Quinn4
1Department of Radiology, Kenneth J. Norris, Jr., Comprehensive Cancer Center, USC Keck School of Medicine, University of Southern California, Los Angeles, California; 2Institute of Urology, Kenneth J. Norris, Jr., Comprehensive Cancer Center, USC Keck School of Medicine, University of Southern California, Los Angeles, California; 3Department of Radiation Oncology, Kenneth J. Norris, Jr., Comprehensive Cancer Center, USC Keck School of Medicine, University of Southern California, Los Angeles, California; and 3Division of Cancer Medicine, Department of Medicine, Kenneth J. Norris, Jr., Comprehensive Cancer Center, USC Keck School of Medicine, University of Southern California, Los Angeles, California
Disclosure
This work was supported in part by grant P30‐CA014089 from the U.S. National Institutes of Health. Dr. Jadvar is on the advisory board of Radiomedix, Inc., and Pharmalogic, is on the speakers’ bureau for Lantheus, and is a consultant to Bayer and Blue Earth Diagnostics. Dr. Abreu is a consultant to Koelis. Dr. Quinn receives payment for advisory board and consulting services to, and is an investigator for, Astellas, Pfizer, Bayer Healthcare, Novartis, and Merck; receives stock options from Abbvie; and is employed by Abbvie. Dr. Ballas is employed by Cedars–Sinai Medical Center. In accordance with ACCME Revised Standards for Commercial Support and SNMMI Conflict-of-Interest Policy, the authors have indicated no other relevant relationships that could be perceived as a real or apparent conflict of interest. Disclosure of a relationship is not intended to suggest or to condone bias but is made to provide participants with information that might be of potential importance to their evaluation of the activity.
Target Audience
This article contains information of value to nuclear medicine professionals interested in the concept of oligometastatic prostate cancer and how nuclear medicine may be contributory, including physicians, technologists, scientists, and those in training.
Objectives
On successful completion of this activity, participants should be able to…
1. Describe the clinical state of oligometastatic disease along the natural history of prostate cancer.
2. Discuss the outcome results of the various clinical trials on metastasis-directed therapy of oligometastatic disease in prostate cancer.
3. Recognize the gaps in knowledge and needed additional areas of research relevant to oligometastatic prostate cancer.
Contact Information
For questions please contact Lisa Dickinson, Associate Director of Education at ldickinson@snmmi.org or 703-652-6783.
